

Supporting Information for Mannich-type C-nucleosidations in the 5,8-diaza-7,9-dicarba-purine family

**Bo Han,[‡] Bernhard Jaun,[‡] Ramanarayanan Krishnamurthy,^{†§} and
Albert Eschenmoser^{*‡⊥}**

*Laboratory of Organic Chemistry, Swiss Federal Institute of Technology,
Hönggerberg, HCI-H309, CH-8093 Zürich, Switzerland
and*

*The Skaggs Institute for Chemical Biology at the Scripps Research Institute,
10550 North Torrey Pines Road, La Jolla, California 92037, USA*

Eschenmoser@org.chem.ethz.ch

^{*} Swiss Federal Institute of Technology

[†] The Scripps Research Institute

[§] Fax ++1-858-784-9573. e-mail: rkrishna@scripps.edu

[⊥] Fax ++41-1-632-1043

Procedures Referring to Scheme 2:

N-formyl-glycyl-guanidine (**5**). This compound was prepared according to Hoffmann's procedure for the synthesis of *N*-formyl-L-valyl-guanidine.¹ Guanidine hydrochloride (15.00 g, 157 mmol) was added to a turbid suspension of NaOMe (8.48 g, 157 mmol) in 200 ml of anhydrous MeOH. The resulting suspension was stirred at rt for 40 min. The formed precipitate, NaCl was filtered off via celite and washed with 50 ml of MeOH. To the colorless filtrate thus obtained was added *N*-formylglycine ethyl ester² (41.14 g, 314 mmol, 2.0 eq) in 20 ml of MeOH. The reaction mixture was stirred at rt for 6 hrs, during which a white precipitate appeared within minutes. After cooling at 4°C for 2 hrs, the white solid was filtered, washed with 50 ml of cold MeOH, dried (HV, rt, overnight) to give 15.60 g of guanidine **5** as white solid. Yield: 69%; ¹H NMR (300 MHz, DMSO-d₆): δ 3.67 (2H, d, J = 5.1 Hz, NHCH₂), 6.20-8.40 (5H, m, NH × 5), 8.03 (1H, s, CHO); ¹³C NMR (75 MHz, DMSO-d₆): δ 44.05, 161.07, 162.23, 179.40; ESI MS: m/e 145.3 (28, M+H⁺), 167.2 (20, M+Na⁺), 289.2 (52, 2M+H⁺), 311.2 (100, 2M+Na⁺).

2-Amino-4-formylaminomethyl-6-trichloromethyl-s-triazine (**6**)³. To a suspension of guanidine **5** (14.4 g, 0.1 mol) in 100 ml of DMF was added dropwise of Cl₃CCN (28.8 g, 0.2 mol, 2eq). After adding, the reaction mixture was stirred at r.t. for 30 min until the solution became clear. After heating at 80°C (bath temperature) for 1 hr, the light brown solution was evaporated to dryness. The white solid thus obtained was washed with H₂O (200 ml), dried under HV over P₂O₅ to give 26.5 g of triazine **6** as white solid.⁴ Yield: 98%; ¹H NMR (300 MHz, DMSO-d₆): δ 4.29 (2H, d, J = 6.0 Hz, CH₂), 8.15 (1H, d, J = 1.2 Hz, CHO), 8.23 (1H, br, NH₂), 8.27 (1H, br, NH₂), 8.51 (1H, t, J = 5.7 Hz, NHCHO); ¹³C NMR (75 MHz, DMSO-d₆): δ 42.89, 95.99, 161.28, 166.87, 172.06, 176.65; ESI MS (negative): m/e 268.0 (100, [M-H]⁻), 270.0 (96), 272.0 (30).

4-Amino-6-formylaminomethyl-1H-[1,3,5]triazin-2-one (**7**). Triazine **6** (13.5 g, 50 mmol) was suspended in 250 ml of 0.8 M aq. Na₂CO₃ solution. The reaction mixture was stirred at 80°C for 2 hrs, at which time **6** was gradually dissolved and a clear light yellow solution was obtained. TLC (CHCl₃/MeOH, 25% aq. NH₃) showed the consumption of **6** (Rf 0.86) and the formation of a major product (Rf 0.22). The reaction mixture was cooled to 0°C, and neutralized with conc. aq. HCl to pH7. The white precipitate was filtered, washed with H₂O (2× 100 ml), MeOH (2× 100 ml), and diethyl ether (2× 100 ml) to give 7.1 g of 4-amino-6-formylaminomethyl-1H-[1,3,5]triazin-2-one **7** as white solid.⁵ Yield: 83%; ¹H NMR (300 MHz, DMSO-d₆): δ 4.05 (2H, d, J = 6.0 Hz, CH₂), 7.38 (1H, br, NH₂), 7.51 (1H, br, NH₂), 8.10 (1H, s, CHO), 8.36 (1H, t, J = 5.7 Hz, NHCHO), 11.54 (1H, br, NH); ¹³C NMR (75 MHz, DMSO-d₆, 60°C): δ 40.48, 156.00, 161.61, 165.06, 168.85; ESI MS (positive): m/e 191.9 (100, M+Na⁺).

¹ Hoffmann, E.; Diller, D. *Can. J. Chem.* **1965**, *43*, 3103.

² Martin, P. K.; Matthews, H. R.; Rapoport, H.; Thyagarajan, G. *J. Org. Chem.* **1968**, *33*, 3758.

³ Trichloroacetonitrile has been used for the synthesis of 2-amino-4-alkyl-6-trichloromethyl-s-[1,3,5]triazine. Kelarev, V. I.; Ammar Dibi; Lunin, A. F. *Chem. Heterocycl. Compd. (New York)*, **1985**, *21*, 1284, Engl. Transl. From Khim. Geterotsikl. Soedin. (Russian) 1985, *21*, 1557.

⁴ Triazine **6** can be dissolved well in MeOH. It is sparingly soluble in H₂O.


⁵ Triazin-2-one **7** is soluble in DMSO, and non-soluble in CH₂Cl₂, MeOH, and H₂O.

*2-amino-6-oxo-5, 8-diaza-7, 9-dicarbapurine (2)*⁶. Triazin-2-one **7** (4.23 g, 25 mmol) was dissolved in 40 ml of 98% H₂SO₄, and the resulting light brown solution was stirred at 100°C for 5 hrs. After cooling to rt, the acid solution was carefully poured into 500 ml of rapid stirred ether. The ether was decanted and fresh ether was added; this sequence was repeated twice. The precipitated salt was suspended in 100 ml of H₂O and the solution was made basic (pH=9) by adding 25% aq. NH₃. To the clear light brown solution thus obtained was added dropwise AcOH until pH=6.5. The light brown precipitate formed was filtered, washed with 50 ml of cold H₂O, and dried under HV over P₂O₅ to give 3.21 g of purine **2** as light brown solid.⁷ Yield: 85%; Rf: 0.33 (CH₂Cl₂/MeOH, 4/1); ¹H NMR (300 MHz, DMSO-d₆): δ 6.46 (2H, s, NH₂), 6.52 (1H, d, ⁴J = 0.9 Hz, H-9), 7.93 (1H, d, ⁴J = 0.9 Hz, H-7), 11.17 (1H, br, NH); ¹³C NMR (75 MHz, DMSO-d₆): δ 111.66 (C-9), 125.37 (C-7), 137.79, 145.08, 149.45; ESI MS (positive): 152.1 (100, M+H⁺), 303.1 (20, 2M+H⁺), 325.1 (24, 2M+Na⁺); ESI MS (negative): m/e 150.0 (100, [M-H]⁻), 301.0 (32, [2M-H]⁻), 452.0 (4, [3M-H]⁻). UV (C = 2.50×10⁻⁴M in pH =7 0.1 M phosphate buffer): ε (220nm) = 10200; λ_{max} = 261nm (ε = 7300).

2-(N,N-dimethylaminomethyleneamino)-6-oxo-5,8-diaza-7,9-dicarbapurine (8). To a solution of purine **2** (225 mg, 1.5 mmol) in 25 ml of MeOH was added dimethylformamide dimethylacetal (1.79 g, 15.0 mmol, 10 eq) in one portion. The reaction solution was stirred at rt for 12hrs. TLC (CH₂Cl₂/MeOH, 4/1) showed the consumption of starting compd. **2** (Rf 0.29) and the formation of two new spots (Rf 0.41, 0.73). The clear yellow solution was evaporated under reduced pressure at 35 °C to dryness. The yellow oil residue was dissolved in CH₂Cl₂/MeOH (10/1) and loaded onto a silica gel column. Chromatography was conducted using CH₂Cl₂/MeOH (10/1) as eluent. Fractions containing the fast moving product were combined, evaporated, and dried to give 245 mg of **8** as white solid. Yield 79%; Rf 0.52 (CH₂Cl₂/MeOH, 10/1); ¹H NMR (300 MHz, DMSO-d₆): δ 3.05 (3H, s, CH₃), 3.16 (3H, s, CH₃), 6.75 (1H, s, H-7), 8.04 (1H, s, H-9), 8.61 (1H, s, -N=CH-), 11.61 (1H, br, NH); ¹³C NMR (75 MHz, DMSO-d₆): δ 34.79, 40.74, 114.71, 125.92, 138.08, 145.05, 152.74, 158.17; ESI MS: m/e 207.2 (52, M+H⁺), 435.1 (100, 2M+Na⁺); Colorless crystals were obtained after crystallization of **6** in MeOH. A colorless, cubic crystal was mounted to collect X-ray data. m.p.(MeOH) >179°C (decomp.).

⁶ Conc. H₂SO₄ has been successfully used in the cyclization of 2-amino-4-(2-hydroxyvinyleneamino)-s-triazin-4-one to give 5-aza-7-carbaguanine. Kim, S.H.; Bartholomew, D.G.; Allen, L.B.; Robins, R.K.; Revankar, G.R.; Dea, P. *J. Med. Chem.* **1978**, 21, 883.

⁷ Purine **2** can be dissolved in DMF, DMSO, hot H₂O and hot MeOH. It is not soluble in ether, CH₂Cl₂. It is thermally stable for 10 hrs at 190°C, and underwent slow sublimation.


X-ray of Purine 8.⁸

Fractions containing the slow moving product were combined, evaporated, and dried to give 36 mg of 2-(N,N-dimethylaminomethyleneamino)-9-(N,N-dimethylaminomethylene)-6-oxo-5,8-diaza-7,9-dicarbapurine⁹ as yellow solid. Yield 9%; Rf 0.19 (CH₂Cl₂/MeOH, 10/1); ¹H NMR (300 MHz, DMSO-d₆): δ 3.01 (3H, s, H-16), 3.14 (3H, s, H-16), 3.48 (3H, s, H-12), 3.74 (3H, s, H-12), 8.19 (1H, s, H-7), 8.25 (1H, s, H-10), 8.74 (1H, s, H-14); ¹³C NMR (125 MHz, DMSO-d₆): δ 34.58 (C-16), 40.59 (C-16), 40.82 (C-12), 47.26 (C-12), 115.85 (C-9), 131.88 (C-7), 147.96 (C-10), 150.04 (C-6), 158.51 (C-4), 159.54 (C-14), 169.25 (C-2) (assignment of ¹H and ¹³C were based on difference-NOE and HMBC); ESI MS (positive): m/e 262.3 (100, M+H⁺), 284.2 (40, M+Na⁺), 300.0 (12, M+K⁺), 523.2 (5, 2M+H⁺), 545.1 (80, 2M+Na⁺), 561.1 (8, 2M+K⁺).

4,6-diamino-2-formylaminomethyl-s-triazine (**9**)¹⁰. Triazine **6** (540mg, 2 mmol) was dissolved in 50 ml of saturated NH₃ in MeOH. The reaction solution was left 48 hrs at rt without stirring. The formed colorless needles were filtered, washed with ether and dried under HV at rt overnight to give 276 mg of 4,6-diamino-2-formylaminomethyl-s-triazine **9**. Yield 82%; m.p. >275°C (decomp.); ¹H NMR (300 MHz, DMSO-d₆): δ 8.19 (1H, br, NH), 8.09 (1H, s, CHO), 6.68 (4H, br, 2 × NH₂), 3.97 (2H, d, J = 6.0 Hz, CH₂); ¹³C NMR (75 MHz, DMSO-d₆): δ 42.59 (CH₂), 161.19 (CHO), 166.93 (C-4, C-6), 174.01 (C-2).

⁸) x-ray structure analysis of **8** was carried out by Dr. Bernd Schweizer, ETH-Z. Crystallographic data for the structure has been deposited with the Cambridge Crystallographic Data Center as deposition no. CCDC 242452. Copies of the data can be obtained, free of charge, on application to the CCDC, 12 union Road, Cambridge CB12 1EZ, UK (fax +44 (1233) 336 0333; e-mail: deposit@ccdc.cam.ac.uk).

⁹ Structure of 2-(N,N-dimethylaminomethyleneamino)-9-(N,N-dimethylaminomethylene)-6-oxo-5,8-diaza-7,9-dicarbapurine:



¹⁰ Triazine **9**, the precursor compd. for the synthesis of 2,6-Diamino-5,8-diaza-7,9-dicarba-purine, has been reported by Wang et al. using the reaction of N-formylglycine ethyl ester with biguanide. Wang, Z.; Huynh, H. K.; Han, B.; Krishnamurthy, R.; Eschenmoser, A. *Org. Lett.* **2003**, 5, 2067. The present method offered another convenient route to the synthesis of **9**.

Procedures Referring to Scheme 3:

N-cyano-isocyanate-dimethylacetal¹¹. Cyanamide (Aldrich 99%, 15.5 g, 0.37 mol) was dissolved in tetramethyl orthocarbonate (50.0 g, 0.37 mol, 1eq), and the reaction was heated at 95 °C before removing MeOH (ca 21 g) by distillation under atmospheric pressure. After evaporated at 90 °C (bath temperature) under reduced pressure (0.2 mmHg), the light yellow liquid residue was left at 4 °C for 4 hrs. After adding 10 ml of cold ether, the colorless solid was filtered and dried under vacuum (60 mmHg) to give 31.3 g of *N*-cyano-isocyanate-dimethylacetal as colorless crystal. Yield: 76%; m.p. 56-58 °C (lit.¹² 52-56°C); ¹H NMR (300 MHz, DMSO-d₆): δ 3.93 (6H, 2 × CH₃); ¹³C NMR (75 MHz, DMSO-d₆): δ 58.46 (CH₃), 113.00 (>CH=), 164.36 (CN); EI MS: m/e 114.0 (54, M⁺), 69.0 (100).

2-methoxy-6-amino-5,8-diaza-7,9-dicarbapurine (10). A suspension of 4-nitroimidazole (11.3 g, 0.1 mol, ACROS 98%) and 10% Pd/C (4.5 g, 40% w/w, Fluka) in 250 ml dried 1,4-dioxane (distilled over sodium) was stirred vigorously under atmospheric pressure of H₂ for 12 hrs until TLC showed the total disappearance of 4-nitroimidazole (Rf 0.50, CH₂Cl₂/MeOH/25% aq NH₃, 5/1/0.1) and the formation of 4-amino-imidazole (Rf 0.30, CH₂Cl₂/MeOH/25% aq NH₃, 5/1/0.1). Under Ar, the catalyst was filtered off (closed two branched flask). At r.t., *N*-cyano-isocyanate-dimethylacetal (11.4 g, 0.1 mol, 1eq) was then added dropwise as pure solid to the filtrate. After adding, the reaction mixture was heated at 80 °C for 3 hrs until TLC showed the consumption of 4-amino-imidazole and the formation of a major new UV active spot (Rf 0.57, CH₂Cl₂/MeOH/25% aq NH₃, 5/1/0.1). After adding silica gel (25 g), the reaction mixture was evaporated at 40°C under reduced pressure to dryness. The resulting silica gel containing product was loaded onto silica gel column and eluted with CH₂Cl₂/MeOH (8/1). Fractions containing product were collected and evaporated to dryness to give 3.49 g of purine **10** as white solid. Yield: 21%; Rf: 0.51 (CH₂Cl₂/MeOH, 6/1); ¹H NMR (300 MHz, DMSO-d₆): δ 3.79 (3H, s, CH₃), 6.86 (1H, d, J = 0.6 Hz, H-7), 8.22 (1H, d, J = 0.6 Hz, H-9), 8.49 (2H, br, NH₂); ¹³C NMR (75 MHz, DMSO-d₆): δ 53.80, 112.51, 122.51, 139.15, 149.53, 159.97; ESI MS: m/e 166.1 (100, M+H⁺); EI MS: m/e 165.0 (100, M⁺), 135.0 (11), 108.99 (32), 107.99 (73).

2-oxo-6-amino-5,8-diaza-7,9-dicarbapurine (3). Purine **10** (1.65 g, 10mmol) was suspended in 50 ml of 33% HBr/AcOH (Fluka). The reaction mixture was stirred at r.t. for 12 hrs. After evaporation of the excess HBr and AcOH under HV (liquid N₂ trap) at r.t., the resulting light yellow solid residue was stirred in 80 ml of MeOH for 20 min. The white solid was filtered, washed with MeOH (20 ml), ether (50 ml), and dried at r.t. under HV to give 1.63 g 2-oxo-6-amino-5,8-diaza-7,9-dicarbapurine hydrobromides which was neutralized directly with 25% aq ammonia. Thus to a suspension of 1.60 g of 2-oxo-6-amino-5,8-diaza-7,9-dicarbapurine hydrobromides in 50 ml of H₂O (pH 1.7) was added dropwise 25% aq ammonia until pH = 10. The suspension was sonicated (ultra sound bath) for 30 min at rt. The white precipitate was filtered, washed with H₂O (25 ml), and dried under HV at rt to give 998 mg of purine **3** as white

¹¹ Tetramethyl orthocarbonate was used instead tetraethyl orthocarbonate in order to avoid the formation of a mixture of O- and N- ethylated isomers. Kantelehner, W.; Maier, T.; Löffler, W.; Kapassakalidis J.J. *Liebigs Ann. Chem* **1982**, 507.

¹² Heitke, B. T.; McCarty, C. G. *J. Org. Chem.* **1974**, 39, 1522.

solid. ¹³Yield 66%; ¹H NMR (300 MHz, DMSO-d₆): δ 6.31 (1H, s, H-7), 8.08 (1H, s, H-9), 8.26 (2H, br, NH₂), 10.84 (1H, br, NH); ¹³C NMR (75 MHz, DMSO-d₆): δ 104.44, 124.12, 132.31, 148.55, 153.28; ESI MS: m/e 152.0 (61, M+H⁺), 184.0 (100, M+MeOH+H⁺), 302.9 (59, 2M+H⁺); UV (C = 2.52×10⁻⁴M in pH =7 0.1 M phosphate buffer): ε (220nm) = 24400; λ_{sh} = 240nm (ε = 5200); ε (ca 290nm) = 1000.

4-(imidazol-4'-yl)-allophanic acid phenyl ester (11). A suspension of 4-nitroimidazole (11.3 g, 0.1 mol, ACROS 98%) and 10% Pd/C (4.5g, 40% w/w, Fluka) in 250 ml dried 1,4-dioxane (distilled over sodium) was stirred vigorously under atmospheric pressure of H₂ for 12 hrs until TLC showed the total disappearance of 4-nitroimidazole (Rf 0.51, CH₂Cl₂/MeOH/25% aq NH₃, 5/1/0.1) and the formation of 4-amino-imidazole (Rf 0.28, CH₂Cl₂/MeOH/25% aq NH₃, 5/1/0.1). Under Ar, the catalyst was filtered off (closed two branched flask) and phenoxycarbonyl-isocyanate¹⁴ (16.3g, 0.1 mol, 1.0 eq) was added dropwise as pure liquid to the filtrate. The reaction mixture was stirred at rt for 2 hrs. TLC showed the formation of a major new compd. (Rf 0.68, CH₂Cl₂/MeOH/25% aq NH₃, 5/1/0.1). After adding silica gel (5.0 g), the reaction mixture was evaporated at 30°C under reduced pressure to dryness. The resulting silica gel containing product was loaded onto silica gel column and eluted with CH₂Cl₂/MeOH (8/1). Fractions containing product (Rf 0.30, CH₂Cl₂/MeOH, 8/1) were collected and evaporated at 30°C under reduced pressure to give 7.9 g of ester **11** as white solid. Yield: 32%; Rf 0.58 (CH₂Cl₂/MeOH, 6/1); ¹H NMR (300 MHz, DMSO-d₆): δ 7.04 (1H, s, =CH- of imidazole), 7.23-7.47 (6H, m, C₆H₅ and =CH- of imidazole), 9.62 (1H, br, NH), 10.85 (1H, br, NH), 11.91 (1H, br, NH); ¹³C NMR (75 MHz, DMSO-d₆): δ 102.43, 121.88, 126.19, 129.61, 136.04, 148.94, 149.80, 13.09; ESI MS: m/e 247.1 (7, M+H⁺), 269.1 (41, M+Na⁺), 515.1 (100, 2M+Na⁺); HR ESI: Anal. Calcd. for C₁₀H₁₁N₄O₃Na 269.0645. Found: 269.0648.


*2,6-dioxo-5,8-diaza-7,9-dicarbapurine (4)*¹⁵. Ester **11** (7.15 g, 29 mmol) was suspended in 150 ml of EtOH. The reaction mixture was heated under reflux for 3 hrs, in which time starting material was dissolved within 10 min, and a white precipitate was produced there after. After cooling at 4°C overnight, the white precipitate was filtered, washed with dry ether to give 3.81 g of 2,6-dioxo-5,8-diaza-7,9-dicarbapurine **4** as white solid.¹⁶ Yield: 86%; Rf: mp > 250 °C (decomp.); ¹H NMR (300 MHz, DMSO-d₆): δ 6.40 (1H, d, J = 0.9 Hz, H-9), 7.99 (1H, d, J = 0.9 Hz, H-7), 11.50 (2H, br, 2 × NH); ¹³C NMR (75 MHz, DMSO-d₆): δ 107.12, 127.20, 129.19, 144.32, 148.23; EI MS: m/e 152.0 (31, M⁺), 109.0 (68), 54.1 (100); UV (C = 2.33×10⁻⁴M in pH =7, 0.1 M phosphate buffer): ε (220nm) = 4300; λ_{max} = 237nm (ε = 5900). Colorless crystals were obtained by crystallization of **4** in EtOH. A colorless, cubic crystal was mounted to collect X-ray data.

¹³ Purine **3** is sparingly dissolved in DMSO and not soluble in MeOH, H₂O. It is thermally stable at 190 °C for 10 hrs. ¹H, ¹³C NMR sample was obtained by filtration of the suspension of **3** in DMSO-d₆.

¹⁴ Ramirez, F.; Telefus, C. D.; and Prasad, V. A. V. *Tetrahedron*, **1975**, *31*, 2007.

¹⁵ Phenoxycarbonyl-isocyanate has been used for the synthesis of 5-aza-7-carboxanthine. Rao, P.; Benner S. A. *J. Org. Chem.* **2001**, *66*, 5012.

¹⁶ Purine **4** is soluble in DMSO, hot H₂O and hot MeOH. It is partially dissolved in DMF.

X-ray of purine **4**.¹⁷

Procedures Referring to Scheme 4:

2-amino-6-oxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*R*,3'*S*)-2',3'-di(*tert*-butyloxycarbonylamino)-(1'*R*)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine (**13α**) and 2-amino-6-oxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*R*,3'*S*)-2',3'-di(*tert*-butyloxycarbonylamino)-(1'*S*)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine (**13β**). Into the solution of 2-amino-6-oxo-5,8-diaza-7,9-dicarbapurine **2** (302 mg, 2.0 mmol) and pyrroline **12**¹⁸ (660 mg, 2.2 mmol, 1.1 eq) in 10 ml of DMF was added *p*-toluenesulfonic acid monohydrate (380 mg, 2.0 mmol, 1.0 eq). The reaction mixture was stirred at room temperature for 2 hrs. T.L.C (CH₂Cl₂/MeOH, 4/1) revealed the total consumption of **5** (R_f 0.34) and formation of a new spot (R_f 0.10). Then Et₃N (1.01, 10.0 mmol, 5.0 eq) added in one portion to the reaction mixture, followed by the dropwise adding of Boc₂O (480 mg, 2.2 mmol, 1.1 eq) in 2 ml of CH₂Cl₂. The reaction mixture was stirred at room temperature for 2 hrs, after which TLC (CH₂Cl₂/MeOH, 4/1) showed the spot with the R_f 0.10 was consumed with the formation of another main spot (R_f 0.86). The reaction solution was evaporated till dryness gave light yellow foam, upon which 150 ml of ethyl acetate was added. The whole solution was washed with water (3 × 50 ml), dried over Na₂SO₄, and concentrated under reduced pressure at 30 °C to yield a pale yellow foam. The crude product was purified by column chromatography on silica gel using CH₂Cl₂/MeOH (100/3 to 100/5) gave 765 mg (70%) of pure α-epimer **13α** and 240mg (22%) of pure β-epimer **13β** in the molecular ratio of α/β = 3.2/1.

13α: colorless solid, R_f 0.30 (CH₂Cl₂/MeOH, 10/1); ¹H NMR (300MHz, 100°C, DMSO-*d*₆): δ 1.19 (9H, s, 3× CH₃), 1.32 (9H, s, 3× CH₃), 1.40 (9H, s, 3× CH₃), 3.23 (1H, dd, ³J = 7.2 Hz, ²J = 10.5 Hz, *Re*-H-4'), 3.75 (1H, dd, ³J = 5.9 Hz, ²J = 10.5 Hz, *Si*-H-4'), 3.98 (2H, m, H-2', H-3'), 4.64 (1H, d, J = 5.3 Hz, H-1'), 6.22 (2H, br, NH₂), 6.78 (1H, br, NHBoc), 7.08 (1H, br, NHBoc), 7.89 (1H, s, H-7), 10.83 (1H, br, H-1); MALDI MS: *m/e* 573.3(80, M+Na⁺), 551.3 (12, M+H⁺), 473.2 (100, M-Boc+Na⁺), 451.2 (42, M-Boc+H⁺), 373.2 (46, M-2Boc+Na⁺), 351.2 (34, M-2Boc+H⁺), 273.0 (6, M-3Boc+Na⁺), 251.1 (10, M-3Boc+H⁺); HRMALDI MS: *m/e* (M+Na⁺) found 573.2764, C₂₄H₃₈N₈O₇Na requires 573.2756; UV (C = 9.53×10⁻⁵ M in MeOH): ε (220nm) = 6000, λ_{max} = 266 nm (ε = 11000).

¹⁷ X-ray structure analysis of **4** was carried out by Dr. Bernd Schweizer, ETH-Z. Crystallographic data for the structure has been deposited with the Cambridge Crystallographic Data Center as deposition no. CCDC 242453. Copies of the data can be obtained, free of charge, on application to the CCDC, 12 union Road, Cambridge CB12 1EZ, UK (fax +44 (1233) 336 0333; e-mail: deposit@ccdc.cam.ac.uk).

¹⁸ Han, B.; Wang, Z.; Krishnamurthy, R., Jaun, B., Eschenmoser, A. *Org. Lett.* **2003**, 5, 2071.

13β: colorless solid, Rf 0.25 (CH₂Cl₂/MeOH, 10/1); ¹H NMR (300MHz, 100°C, DMSO-d₆): δ 1.25 (9H, s, 3× CH₃), 1.30 (9H, s, 3× CH₃), 1.40 (9H, s, 3× CH₃), 3.13 (1H, dd, ³J = 8.4 Hz, ²J = 10.0 Hz, *Re*-H-4'), 3.73 (1H, dd, ³J = 8.7 Hz, ²J = 10.0 Hz, *Si*-H-4'), 4.09 (1H, q, J ≈ 8.7 Hz, H-2'), 4.48 (1H, br. qi, J ≈ 8.7 Hz, H-3'), 5.03 (1H, d, J = 7.5 Hz, H-1'), 5.28 (1H, br, NHBoc), 6.18 (2H, br, NH₂), 6.67 (1H, d, J = 7.2 Hz, NHBoc), 7.90 (1H, s, H-7), 10.81 (1H, br, H-1); MALDI MS: m/e 573.3(100, M+Na⁺), 552.3 (18, M+H⁺), 473.2 (76, M-Boc+Na⁺), 451.2 (65, M-Boc +H⁺), 373.2 (39, M-2Boc+Na⁺), 351.2 (54, M-2Boc +H⁺), 273.0 (6, M-3Boc+Na⁺), 251.1 (14, M-3Boc +H⁺); HRMALDI MS: m/e (M+Na⁺) found 573.2763, C₂₄H₃₈N₈O₇Na requires 573.2756. UV (C = 8.42×10⁻⁵ M in MeOH): ε (220nm) = 5500, λ_{max} = 266 nm (ε = 10200).

2-amino-6-oxo-9-[(2'R,3'S)-2',3'-diamino-(1'R)-pyrrolidinyl]-5,8-diaza-7,9-dicarba-purine hydrochlorides (14α) Nucleoside **13α** (150 mg, 0.27 mmol) was added in one portion to 20 ml of saturated HCl in MeOH. After the reaction solution was stirred at rt for 30 min, solvent and excess of HCl was evaporated to dryness. The white solid residue was co-evaporated twice with toluene and dried under HV at rt overnight to give 102 mg of 2-amino-6-oxo-9-[(2'R,3'S)-2',3'-diamino-(1'R)-pyrrolidinyl]-5,8-diaza-7,9-dicarba-purine hydrochlorides **14α** as white solid. Yield: 95% (calculated according to the corresponding tetrahydrochlorides); ¹H NMR (300MHz, AcOH-d₄/D₂O, 5/2): δ 4.00 (1H, dd, J = 6.0, 13.6 Hz, *Re*-H-4'), 3.80 (1H, dd, J = 9.3, 13.6 Hz, *Si*-H-4'), 4.54 (1H, ddd, J_{H2', H3'} = 5.8 Hz, J_{H3', Si-H4'} = 8.8 Hz, J_{H3', Re-H4'} = 6.0 Hz, H-3'), 5.06 (1H, dd, J_{H1', H2'} = 7.4 Hz, J_{H3', H2'} = 5.8 Hz, H-2'), 5.52 (1H, d, J = 7.4 Hz, H-1'), 8.37 (1H, s, H-7); ¹³C NMR (300MHz, AcOH-d₄/D₂O, 5/2): δ 46.98 (C-4'), 51.96 (C-3'), 55.97 (C-2'), 74.43 (C-1'), 110.50 (C-9), 128.18 (C-7), 137.89, 144.41, 151.30; ESI MS: m/e 251.1 (M+H⁺, 100).

2-amino-6-oxo-9-[(2'R,3'S)-2',3'-diamino-(1'S)-pyrrolidinyl]-5,8-diaza-7,9-dicarba-purine hydrochlorides (14β). Following the procedure for the preparation of **14α**, from **13α**, **14β** was prepared from **13β**; Yield: 100% (calculated according to the corresponding tetrahydrochlorides); ¹H NMR (300MHz, AcOH-d₄/D₂O, 5/2): δ 3.98 (1H, dd, J = 6.0, 13.5 Hz, *Re*-H-4'), 4.36 (1H, dd, J = 9.3 13.0 Hz, *Si*-H-4'), 4.98 (1H, dd, J_{H1', H2'} = 7.9 Hz, J_{H3', H2'} = 6.7 Hz, H-2'), 5.15 (1H, ddd, J_{Si-H4', H3'} = 9.3 Hz, J_{Re-H4', H3'} = 6.0 Hz, J_{H2', H3'} = 6.7 Hz, H-3'), 5.87 (1H, d, J = 7.9 Hz, H-1'), 8.32 (1H, s, H-7); ¹³C NMR (300MHz, AcOH-d₄/D₂O, 5/2): δ 46.50 (C-4'), 52.46 (C-3'), 54.65 (C-2'), 55.91 (C-1'), 110.02 (C-9), 128.79 (C-7), 137.18, 144.48, 151.49; ESI MS: m/e 251.0 (M+H⁺, 100).

Procedures Referring to Scheme 5:

*9-[N-(tert-butyloxycarbonyl)-(2'S,3'S)-2',3'-dibenzoyloxy-1'-pyrrolidinyl]-5,8-diaza-7,9-dicarba-purines (16-19)*¹⁹. General procedure: Into a solution of 5,8-diaza-7,9-dicarba-purine (2.0

¹⁹ The assignment of the configuration of the anomeric center in the epimeric pairs **16α/β**, **17α/β**, **18α/β**, and **19α/β** (Scheme 5) is based on the following observations: Due to slow rotamer interconversion at room temperature, the ¹H-NMR spectra (DMSO-d₆, 300-500 MHz) of all N-Boc protected compounds showed broad lines, whereas at 70°C, the signals were sharp. In each pair, coupling constants J_{1,2'} and J_{2,3'} were small in the α-isomer and large for the β-isomer. Compared to the α-isomer, the signals of H1' and H3' were shifted to low field by ca. 0.2 ppm in β-isomer. On the basis of this consistent pattern, the configuration of the two isomers was determined for **18α/18β** from the coupling constants and DPFGSE-NOE build-up curves at 70°C and was carried over to the other pairs by analogy.

mmol) and (3*S*, 4*S*)-3, 4-dibenzoyloxypyrroline trimer **15**¹⁶ (1.85 g, 2.0 mmol, 1.0 eq) in 20 ml of DMSO was added *p*-toluenesulfonic acid monohydrate (380 mg, 2.0 mmol, 1.0 eq). The reaction mixture was stirred at room temperature until T.L.C revealed the consumption of 5,8-diaza-7,9-dicarbapurine (6 hr for **2** and **3**, 24 hr for **4**, 72 hr for 2-deamino-**1**). Then Et₃N (1.01 g, 10.0 mmol, 5.0 eq) in 2 ml of CH₂Cl₂ was added in one portion to the reaction mixture, followed by the dropwise adding of Boc₂O (480 mg, 2.2 mmol, 1.1 eq) in 2 ml of CH₂Cl₂. The reaction mixture was stirred at room temperature for 2 hrs. The reaction solution was evaporated at 50°C under HV till dryness to give light brown oil. Column chromatography (AcOEt/iPrOH/10/1 for **16**; CH₂Cl₂/MeOH/10/1 for **17**; AcOEt/hexane/1/1 to 2/1 for **18**; AcOEt/hexane/9/1 for **19**) gave **16-19** as epimeric mixtures.

Data for 2-amino-6-oxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-dibenzoyloxy-1'-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine **16α, β** (**16α/β** = 1.2/1, ¹H NMR from epimeric mixture): 858 mg brown solid; yield 77%; R_f 0.72 (CH₂Cl₂/MeOH/25% aq. NH₃ = 5/1/0.1), 0.44 (CH₂Cl₂/iPrOH=10/1); ¹H NMR (300Mz, DMSO-d₆, 80°C); δ 1.28, 1.30 (s, s, 9H, 3 × CH₃), 3.54 (0.45H, dd, ²J = 5.0, 11.9 Hz, *Re*-H-4'-β), 3.76 (0.55H, dd, ²J = 4.4, 11.9Hz, *Re*-H-4'-α), 4.23 (1H, m, *Si*-H-4'), 5.12 (0.55H, d, J = 2.5 Hz, H-1'-α), 5.43 (0.45H, d, J = 7.2 Hz, H-1'-β), 5.56 (0.55H, dt, J = 6.0, 4.0 Hz, H-3'-α), 5.76 (0.45H, dd, J = 5.3, 2.5 Hz, H-2'-β), 5.77 (0.55H, t, J = 7.0 Hz, H-2'-α), 5.96 (0.45H, ddd, J = 6.0, 6.0, 7.0 Hz, H-3'-β), 6.20, 6.24 (br, br, 2H, NH₂), 7.20-8.20 (m, 11H, 2 × C₆H₅, H-7), 10.80 (br, 1H, NH); MALDI MS: m/e 583.1 (26, M+Na⁺), 561.2 (10, M+H⁺), 483.1 (31, M-Boc+Na⁺), 461.1 (100, M-Boc+H⁺); HRMALDI: m/e (M+Na⁺) found 583.1919, C₂₈H₂₈N₆O₇Na requires 583.1912; UV (C = 9.39 × 10⁻⁵ M in MeOH): ε(231 nm) = 29900, λ_{max} = 267 nm (ε = 11900).

Data for 2-oxo-6-amino-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-dibenzoyloxy-1'-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine **17α, β** (**17α/β** = 1.7/1, ¹H NMR from epimeric mixture): 920 mg brown solid; yield 82%; R_f 0.78 (CH₂Cl₂/MeOH/25% aq. NH₃ = 5/1/0.1), 0.33 (CH₂Cl₂/MeOH= 10/1); ¹H NMR (300Mz, DMSO-d₆, 70°C); δ 1.29 ((9H, br s, 3 × CH₃), 3.61 (0.37H, dd, J = 4.5, 11.7 Hz, *Re*-H-4'-β), 3.73 (0.63H, dd, J = 5.1, 12.7 Hz, *Re*-H-4'-α), 4.14 (0.37 H, dd, J = 6.0, 11.4 Hz, *Si*-H-4'-β), 4.19 (0.63H, dd, J = 6.9, 12.0 Hz, *Si* -H-4'-α), 5.19 (0.63H, d, J = 3.3 Hz, H-1'-α), 5.53 (0.37H, d, J = 6.9 Hz, H-1'-β), 5.57 (0.63H, m, H-3'-α), 7.39-8.12 (13H, m, 2 × C₆H₅, H-7, NH₂), 5.70-5.84 (2.37H, m, H-2'-α, H-2'-β, H-3'-β), 11.70 (1H, br, NH-2); HRMALDI: m/e (M+Na⁺) found 583.1908, C₂₈H₂₈N₆O₇Na requires 583.1912. UV (C = 7.23 × 10⁻⁵ M in MeOH): ε(224 nm) = 41700, λ_{max} = 274 nm (ε = 3200).

2,6-dioxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-dibenzoyloxy-1'-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine **18α, β** (**18α/β** = 1.1/1, ¹H NMR from epimeric mixture): 833 mg brown solid; yield 74%; R_f 0.71 (CH₂Cl₂/MeOH/25% aq. NH₃ = 5/1/0.1), 0.23, 0.30 (AcOEt/Hex=1/1). Preparative HPLC separation (VERTEX COLUMN, Spherisorb SW, JL280, eluted with

NMR data of **18α**: J_{1',2'}=3.1 Hz, J_{2',3'}=3.4 Hz, J_{3',Si-4'}=7.0 Hz, J_{3',Re-4'}=5.1 Hz. Estimated distances from NOE build up rates (calibrated on *Si*-H4'-*Re*-H4'=1.8Å): d(H1'-H2')=2.75Å, d(H1'-H3')=3.2Å, d(H1'-*Si*-H4')=3.6Å, d(H3'-*Re*-H4')=3.9Å.

NMR data of **18β**: J_{1',2'}=6.9 Hz, J_{2',3'}=5.9 Hz, J_{3',Si-4'}=6.7 Hz, J_{3',Re-4'}=4.7 Hz. Estimated distances from NOE build up rates (calibrated on *Si*-H4'-*Re*-H4'=1.8Å): d(H1'-H2')=2.4Å, d(H1'-H3')=3.4Å, d(H1'-*Si*-H4')=3.7Å, d(H3'-*Re*-H4')=3.8Å. These data are consistent with the distances and dihedral angles for a nearly planar five membered ring (in the time average) and the configurations at C1' as indicated.

AcOEt/hexane/2/3, UV 254 detection, flow rate 5 ml/min) of 180 mg of epimeric mixture gave 82 mg of fast moving product and 73 mg of slow moving product.

Data for 2,6-dioxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-dibenzoyloxy-(1'*S*)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine **18α**: fast moving product, t_R 35.0 min; yield 45%; 1H NMR (300Mz, DMSO- d_6 , 70°C); δ 1.31 (9H, br s, 3 \times CH₃), 3.74 (1H, dd, J = 5.1, 11.8 Hz, *Re*-H-4'), 4.21 (1H, dd, J = 7.0, 11.8 Hz, *Si*-H-4'), 5.17 (1H, d, J = 3.1 Hz, H-1'), 5.58 (1H, ddd, $J_{Si-H-4'-H-3'} = 7.0$ Hz, $J_{Re-H-4'-H-3'} = 5.1$ Hz, $J_{H-2'-H-3'} = 3.7$ Hz, H-3'), 7.50-8.05 (11H, m, H-7, 2 \times C₆H₅), 5.71 (1H, dd, $J_{H-1',H-2'} \approx J_{H-3',H-2'} \approx 3.3$ Hz, H-2'), 11.41 (2H, br, 2 \times NH); ^{13}C NMR (100 MHz, DMSO- d_6): δ 27.66 (CH₃), 49.76 (C-4'), 56.78 (C-1'), 74.44 (C-3'), 78.96 (CMe₃), 80.38 (C-2'), 117.55, 125.07, 126.41, 128.07, 128.26, 128.32, 128.83, 128.89, 128.98, 129.13, 132.30, 133.13, 133.22, 143.61, 147.74, 152.95, 164.34 (PhCO), 164.78 (PhCO); ESI MS: m/e 583.9 (M+Na⁺, 100), 562.0 (M+H⁺, 26), 506.0 (M-C₄H₈+H⁺, 50), 484.0 (M-Boc+Na⁺, 100), 462.1 (M-Boc+H⁺, 76); HR MALDI: m/e (M+Na⁺) found 584.1749, C₂₈H₂₇N₅O₈Na requires 584.1757; UV (C = 6.89 $\times 10^{-5}$ M in MeOH): ϵ (231 nm) = 35600, λ_s = 274 nm (ϵ = 6000), λ_s = 282 nm (ϵ = 4900).

Data for 2,6-dioxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-dibenzoyloxy-(1'*R*)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine **18β**: slow moving product, t_R 43.4 min; yield 40%; 1H NMR (300Mz, DMSO- d_6 , 70°C); δ 1.29 (9H, br s, 3 \times CH₃), 3.60 (1H, dd, J = 4.7, 11.5 Hz, *Re*-H-4'), 4.21 (1H, dd, J = 6.7, 11.5 Hz, *Si*-H-4'), 5.17 (1H, d, J = 6.9 Hz, H-1'), 5.84 (2H, m, H-2' and H-3'), 7.40-8.02 (11H, m, H-7, 2 \times C₆H₅), 11.46 (2H, br, 2 \times NH); ^{13}C NMR (100 MHz, DMSO- d_6): δ 27.63 (CH₃), 48.28 (C-4'), 52.91 (C-1'), 73.95 (C-2'), 75.15 (C-3'), 78.77 (CMe₃), 115.52, 125.75, 126.43, 128.07, 128.19, 128.37, 128.65, 128.71, 128.83, 128.86, 128.99, 133.09, 133.25, 143.46, 147.57, 152.92, 164.29 (PhCO), 164.87 (PhCO). ESI MS: m/e 583.9 (M+Na⁺, 100), 562.0 (M+H⁺, 20), 506.0 (M-C₄H₈+H⁺, 39), 484.0 (M-Boc+Na⁺, 76), 462.1 (M-Boc+H⁺, 60); HR MALDI: m/e (M+Na⁺) found 584.1750, C₂₈H₂₇N₅O₈Na requires 584.1757; UV (C = 6.46 $\times 10^{-5}$ M in MeOH): ϵ (231 nm) = 36100, λ_s = 274 nm (ϵ = 4400), λ_s = 282 nm (ϵ = 3500).

Data for 6-amino-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-dibenzoyloxy-1'-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine **19α, β** (**19α/β** = 1.5/1, 1H NMR from epimeric mixture): 702 mg brown solid; yield 64%; R_f 0.32 (AcOEt/hexane = 9/1); 1H NMR (300Mz, DMSO- d_6 , 70°C); δ 1.22 (9H, br s, 3 \times CH₃), 3.60 (0.4H, dd, J = 5.6, 11.5 Hz, *Re*-H-4'-β), 3.78 (0.6H, dd, J = 3.5, 12.4 Hz, *Re*-H-4'-α), 4.21-4.31 (1H, m, *Si*-H-4'-α and *Si*-H-4'-β), 5.34 (0.6H, d, J = 1.9 Hz, H-1'-α), 5.58 (0.6H, ddd, J = 6.6, 3.0, 3.0 Hz, H-3'-α), 5.66 (0.4H, d, J = 7.5 Hz, H-1'-β), 5.84 (1H, m, H-2'-α and H-2'-β), 5.95 (0.4H, m, H-3'-β), 7.32-8.03 (11H, m, 2 \times C₆H₅, -CH=N-), 8.30 (2H, br, NH₂), 8.31 (0.4H, s, -CH=N-β), 8.37 (0.6H, s, -CH=N-α); ESI MS: m/e 567.1 (M+Na⁺, 34), 545.0 (M+H⁺, 100), 489.1 (M-C₄H₈+H⁺, 56), 445.1 (M-Boc+H⁺, 76); UV (C = 5.76 $\times 10^{-5}$ M in MeOH): ϵ (225 nm) = 34700, λ_{max} = 273 nm (ϵ = 11300), λ_s = 283 nm (ϵ = 9100), ϵ (316 nm) = 5600.

2-Amino-6-oxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-hydroxy-(1'*S*)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine (**20α**) and 2-Amino-6-oxo-9-[*N*-(*tert*-butyloxycarbonyl)-(2'*S*,3'*S*)-2',3'-hydroxy-(1'*R*)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine (**20β**). 560 mg (1.0 mmol) of epimeric mixture **16α, β** (**16α/β** = 1.2/1) was dissolved in 300 ml of saturated methanoic ammonia. The reaction mixture was stirred at rt. for 4 days. TLC (CH₂Cl₂/MeOH, 4/1) showed the consumption


of starting material **16α, β** (Rf 0.95) and the formation of two new spots (Rf 0.55, 0.25). After the adding of 5 g of silica gel, the reaction mixture was concentrated to dryness. The resulting brown solid was loaded on a silica gel column (50 g). Elution was conducted using CH₂Cl₂/MeOH (5/1). Fractions contained **20α** and **20β**, respectively, were collected, evaporated and dried under HV gave 169 mg (48%) of **20α** and 155 mg (44%) of **20β**, in the total yield of 92%.

Data for **20α**:²⁰ white solid; fast moving product, Rf 0.55 (CH₂Cl₂/MeOH, 4/1); yield 48%; ¹H NMR (300Mz, DMSO-d₆, 70°C): δ 1.21 (9H, br s, 3 × CH₃), 3.45 (1H, dd, J = 3.1, 11.2 Hz, *Re*-H-4'), 3.68 (1H, dd, J = 5.6, 11.5 Hz, *Si*-H-4'), 3.88 (1H, m, H-3'), 3.95 (1H, br s, H-2'), 4.63 (1H, d, J = 1.8 Hz, H-1'), 5.21 (1H, d, J = 3.3 Hz, OH), 6.01 (1H, br, OH), 6.34 (2H, br, NH₂), 7.96 (1H, s, H-7), 10.98 (1H, br, NH); ¹³C NMR (75Mz, DMSO-d₆, 65°C): δ 28.15, 53.33, 59.89, 74.32, 78.08, 80.71, 122.98, 124.37, 133.35, 144.88, 149.08, 153.78; MALDI MS: m/e 375.1 (M+Na⁺, 46), 353.2 (M+H⁺, 47), 297.1 (M-C₄H₈+H⁺, 60), 253.1 (M-Boc+H⁺, 100); HR MALDI: m/e (M+H⁺) found 353.1571, C₁₄H₂₁N₆O₅ requires 353.1568; UV (C = 8.49 × 10⁻⁵ M in MeOH): ε(220nm) = 7600, λ_{max} = 265 nm (ε = 10200).

Data for **20β**: white solid, slow moving product, Rf 0.25 (CH₂Cl₂/MeOH, 4/1); yield 44%; ¹H NMR (300Mz, DMSO-d₆, 80°C): δ 1.18 (9H, s, 3 × CH₃), 3.15 (1H, dd, J = 4.4, 10.9 Hz, *Re*-H-4'), 3.69 (1H, dd, J = 6.2, 10.9 Hz, *Si*-H-4'), 3.94 ('t', 1H, J ≈ 5.6 Hz, H-2'), 4.22 (1H, ddd, J ≈ 5.0 Hz, H-3'), 4.80 (2H, br, 2 × OH), 4.90 (1H, d, J = 6.2 Hz, H-1'), 8.32 (2H, br, NH₂), 7.87 (1H, s, H-7), 11.80 (1H, br, H-1); ¹³C NMR (75Mz, DMSO-d₆, 80°C): δ 28.07, 51.59, 55.71, 72.71, 77.41, 77.84, 121.23, 124.09, 133.83, 145.21, 149.21, 153.93; MALDI MS: m/e 375.1 (M+Na⁺, 14), 353.2 (M+H⁺, 22), 297.1 (M-C₄H₈+H⁺, 56), 253.1 (M-Boc+H⁺, 100); HR MALDI: m/e (M+H⁺) found 353.1566, C₁₄H₂₁N₆O₅ requires 353.1568. UV (C = 1.02 × 10⁻⁴ M in MeOH): ε(220nm) = 8500, λ_{max} = 265 nm (ε = 9000).

6-amino-9-[N-(tert-butyloxycarbonyl)-(2'S,3'S)-2',3'-hydroxy-(1'S)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine (**21α**) and 2-amino-6-oxo-9-[N-(tert-butyloxycarbonyl)-(2'S,3'S)-2',3'-hydroxy-(1'R)-pyrrolidinyl]-5,8-diaza-7,9-dicarbapurine (**21β**). 444 mg (0.82 mmol) of epimeric mixture **19α, β** (1.5/1) was dissolved in 150 ml of saturated methanoic ammonia. The reaction mixture was stirred at rt. for 48 hr. TLC (CH₂Cl₂/MeOH, 5/1) showed the consumption of starting material **19** (Rf 0.98) and the formation of two new spots (Rf 0.42, 0.21). The reaction solution was evaporated at rt under reduced pressure to dryness to give a yellow oil, which was subject to column chromatography using CH₂Cl₂/MeOH (7/1 to 5/1) as elutant. Fractions contained **21α** and **21β** respectively, were collected, evaporated and dried under HV gave 160 mg (58%) of **21α**, and 90 mg (33%) of **21β** in the total yield of 91%.

²⁰ Configuration of **20α** was further determined by NMR of its corresponding BOC-deprotected product: For 2-amino-6-oxo-9-[(2'S,3'S)-2',3'-dihydroxy-(1'S)-pyrrolidinyl]-5,8-diaza-7,9-dicarba-purine hydrochlorides, with coupling constants J_{1',2'}=3.7 Hz, J_{2',3'}=2.4 Hz, J_{3',*Si*-4'}=4.8 Hz, J_{3',*Re*-4'}=2.6 Hz, together with NOEs H1'-H2'(m), H1'-H3'(m), H1'-*Si*-H4' (w), H2'-*Re*-H4' (m), and H3'-*Si*-H4' (s), indicate a dominantly 3'-endo conformation of the five membered ring with H1' and H3' in *cis* orientation.



Debocylated compd of **20α**

Data for **21 α** : fast moving product, Rf 0.42 (CH₂Cl₂/MeOH, 5/1); yield 58%; ¹H NMR (300Mz, DMSO-d₆, 80°C): δ 1.14 (9H, br s, 3 \times CH₃), 3.37 (1H, dd, J = 5.1, 11.3 Hz, *Re*-H-4'), 3.74 (1H, dd, J = 5.9, 11.2 Hz, *Si*-H-4'), 3.94 (1H, m, H-3'), 4.00 (1H, dd, J = 3.4, 7.5 Hz, H-2'), 4.88 (1H, d, J = 2.8 Hz, H-1'), 5.17 (1H, d, J = 4.1 Hz, OH), 5.70 (1H, br d, J = 8.7 Hz, OH), 7.80 (1H, s, -N=CH-), 8.26 (2H, br, NH₂), 8.34 (1H, s, -N=CH-); ¹³C NMR (100Mz, DMSO-d₆, 80°C): δ 27.65 (q, CH₃), 48.17 (t, C-4'), 59.80 (d, C-1'), 74.26 (d, C-3'), 77.48 (s, CMe₃), 80.77 (d, C-2'), 121.13 (d, C-7), 127.42 (s), 133.79 (s), 148.11 (s), 149.73 (d, C-2), 153.25 (s, C=O of Boc); UV (C = 7.38 \times 10⁻⁵ M in MeOH): ϵ (217 nm) = 13500, λ_{max} = 273 nm (ϵ = 6600), λ_{s} = 284 nm (ϵ = 5000), ϵ (320nm) = 4100; ESI MS (positive): m/e 695.0 (2M+Na⁺, 100); HR ESI: m/e (M+H⁺) found 359.1614, C₁₄H₂₁N₆O₄ requires 359.1619.

Data for **21 β** : slow moving product, Rf 0.21 (CH₂Cl₂/MeOH, 5/1); yield 33%; ¹H NMR (300Mz, DMSO-d₆, 80°C): δ 1.11 (9H, br s, 3 \times CH₃), 3.15 (1H, dd, J = 5.0, 10.9 Hz, *Re*-H-4'), 3.75 (1H, dd, J = 5.6, 10.6 Hz, *Si*-H-4'), 4.03 (1H, dd, J = 5.9, 11.8 Hz, H-2'), 4.29 (1H, ddd, J = 5.5, 5.4, 10.9 Hz, H-3'), 4.48 (1H, d, J = 4.9 Hz, OH), 4.89 (1H, d, J = 4.4 Hz, OH), 5.15 (1H, d, J = 6.5 Hz, H-1'), 7.76 (1H, s, -N=CH-), 8.18 (2H, br, NH₂), 8.29 (1H, s, -N=CH-); ¹³C NMR (100Mz, DMSO-d₆, 80°C): δ 27.60 (q, CH₃), 50.86 (t, C-4'), 55.60 (d, C-1'), 72.43 (d, C-3'), 77.02 (d, C-2'), 77.26 (s, CMe₃), 120.94 (d, C-7), 125.87 (s), 134.71 (s), 148.06 (s), 149.22 (d, C-2), 153.28 (s, C=O of Boc). UV (C = 6.75 \times 10⁻⁵ M in MeOH): ϵ (217nm) = 14800, λ_{max} = 273 nm (ϵ = 6700), λ_{s} = 285 nm (ϵ = 5000), ϵ (321 nm) = 4100; ESI MS (positive): m/e 695.0 (2M+Na⁺, 100); HR ESI: m/e (M+Na⁺) found 359.1434, C₁₄H₂₀N₆O₄Na requires 359.1438.